10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2014

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File No. 333-191725

REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

Nevada	45-5192997
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

619 702 1404

(Issuer’s telephone number)

None

(Former name, address and fiscal year, if changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☑   No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

☐  Large accelerated filer	☐  Accelerated filer
☐  Non-accelerated filer	☑  Smaller reporting company

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of August 2, 2014 there were 51,907,917 shares of common stock issued and outstanding.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes ☐ No ☑

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements

REGEN BIOPHARMA , INC.
(A Development Stage Company)
BALANCE SHEET
	As of			As of
	June 30, 2014			September 30, 2013
	(unaudited)
ASSETS
CURRENT ASSETS
Cash		49,395			115,922
Note Receivable		2,222			0
Accrued Interest Receivable		14			0
Total Current Assets		51,631			115,922
TOTAL ASSETS		51,631			115,922
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable		117			0
Notes Payable		50,000			0
Accrued payroll taxes		7,343			0
Total Current Liabilities		57,460			0
Total Liabilities		57,460			0
STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized;
51,610,000   issued and outstanding as of
September 30, 2013 and 51,907,917 shares issued and outstanding June 30, 2014		5,191			5,161
Preferred Stock($.0001 par value) 5,000,000 shares authorized
0 shares issued and outstanding as of September 30, 2013 and June 30, 2014		0			0
Additional Paid in capital		485,097			185,127
Contributed Capital		587,858			447,858
Retained Earnings (Deficit) accumulated during the development stage		(1,083,975	)		(522,224	)
Total Stockholders' Equity (Deficit)		(5,829)			115,922
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)		51,631			115,922
The Accompanying Notes are an Integral Part of These Financial Statements

REGEN BIOPHARMA , INC.
(A Development Stage Company)
STATEMENT OF OPERATIONS
	Quarter ended		Quarter ended		Nine Months ended		Nine Months ended		From Inception to
									(April 24, 2012) to
	6/30/14		6/30/13		6/30/14		6/30/13		6/30/2014
	(unaudited)		(unaudited)		(unaudited)		(unaudited)		(unaudited)
REVENUES	0		0		0		0		0
COST AND EXPENSES
Research and Development	0		3,000		13,867		8,394		39,976
General and Administrative	127,580		71,829		389,961		228,779		790,025
Consulting and Professional Fees	30,287		0		109,917		0		170,770
Total Costs and Expenses	157,867		74,829		513,745		237,173		1,000,771
OPERATING LOSS	(157,867	)	(74,829	)	(513,745	)	(237,173	)	(1,000,771	)
OTHER INCOME & (EXPENSES)
Interest Income	14		0		14		0		14
Refunds of amounts previously paid	490		0		490		0		35,490
Capital contribution to parent	(8,658	)	0		(48,510	)	0		(118,708	)
TOTAL OTHER INCOME (EXPENSE)	(8,154	)	0		(48,006	)	0		(83,204	)
NET INCOME (LOSS)	(166,021	)	(74,829	)	(561,751	)	(237,173	)	(1,083,975	)
BASIC AND FULLY DILUTED
EARNINGS (LOSS) PER SHARE	(0.00320	)	(0.00310	)	(0.01515	)	(0.02960	)
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING	51,909,907		24,185,714		37,082,956		8,009,891
The Accompanying Notes are an Integral Part of These Financial Statements

REGEN BIOPHARMA , INC.
(A Development Stage Company)
STATEMENT OF CASH FLOWS
		Nine Months			Nine Months			From Inception
		June 30, 2014			June 30, 2013			to June 30, 2014
		(unaudited)			(unaudited)			(unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$	(561,751	)	$	(237,173	)	$	(1,083,975	)
Adjustments to reconcile net Income to net cash
Common Stock issued for expenses	$	0		$	0		$	70,198
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Payable	$	117		$	0		$	117
(Increase) Decrease in Notes Receivable	$	(2,222	)	$	0		$	(2,222	)
(Increase) Decrease in Interest Receivable	$	(14	)	$	0		$	(14	)
Increase (Decrease) in accrued Expenses	$	7,343		$	0		$	7,343
Net Cash Provided by (Used in) Operating Activities	$	(556,527	)	$	(237,173	)	$	(1,008,553	)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash		300,000			20,000			420,090
Increase in Contributed Capital		140,000			219,903			587,858
Increase in Notes Payable		50,000			0			50,000
Net Cash Provided by (Used in) Financing Activities		490,000			239,903			1,057,948
Net Increase (Decrease) in Cash	$	(66,527	)	$	2,730		$	49,395
Cash at Beginning of Period		115,922			923			0
Cash at End of Period	$	49,395		$	3,653		$	49,395
The Accompanying Notes are an Integral Part of These Financial Statements

REGEN BIOPHARMA, INC.

Notes to Financial Statements

As of June 30, 2014

The accompanying financial statements have been prepared by Regen BioPharma, Inc. (“the Company”) without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at June 30, 2014, and for all periods presented herein, have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s September 30, 2013 audited financial statements. . 

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company is a wholly owned subsidiary of Bio-Matrix Scientific Group, Inc, a Delaware corporation.

The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

C. DEVELOPMENT STAGE

The Company is a development stage company devoting substantially all of its efforts to establish a new business.

D. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

E. PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.

F. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level 1:  Quoted prices in active markets for identical assets or liabilities

Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

G. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30 2014 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

H.  BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

I. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarter ended June 30, 2014 and $0 for the twelve months ended September 30, 2013.

NOTE 2.  RECENT ACCOUNTING PRONOUNCEMENTS

The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows.

On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.

On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position.

On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies.  Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $ 1,083,975 during the period from April 24, 2012 (inception) through June 30, 2014. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings.

NOTE 4. NOTES PAYABLE

	June 30, 2014		September 30, 2013
Bio Matrix Scientific Group, Inc. (Note 7)		50,000		0
Notes payable	$	50,000	$	0

$50,000 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

NOTE 5. NOTES RECEIVABLE

	June 30, 2014		September 30, 2013
Entest Biomedical, Inc. (Note 7)		2,222		0
Notes payable	$	2,222	$	0

$2,222 lent by the Company to Entest Biomedical, Inc . is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

NOTE 6. INCOME TAXES

As of June 30, 2014

Deferred tax assets:
Net operating tax carry forwards	$	368,552
Other		-0-
Gross deferred tax assets		368,552
Valuation allowance		(368,552)	)
Net deferred tax assets	$	-0-

As of June 30, 2014 the Company has a Deferred Tax Asset of $368,552 completely attributable to net operating loss carry forwards of approximately $ 1,083,975 (which expire 20 years from the date the loss was incurred).

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. As a result, the Company has the Company recorded a valuation allowance reducing all deferred tax assets to 0.

Income tax is calculated at the 34% Federal Corporate Rate. 

NOTE 7. RELATED PARTY TRANSACTIONS

As of June 30, 2014 the Company has received capital contributions from its parent totaling $587,858 and has issued 50,010,000 common shares to its parent for aggregate consideration of $20,090. The Company also utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 provided to the Company by Entest BioMedical, Inc. on a month to month basis free of charge. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent.

As of June 30, 2014 Entest Biomedical inc. is indebted to the Company in the amount of $2,222. $2,222 lent by the Company to Entest Biomedical, Inc . is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

As of June 30, the Company is indented to its parent in the amount of $50,000. $50,000 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

On August 20, 2013 the Company issued 1,500,000 common shares to the holder of one of its parent’s convertible notes (“Parent Convertible Note Holder”) in satisfaction of $70,198 owed by the Company’s parent to the Parent Convertible Note Holder. During the three months ended December 31, 2013

(1) The Company has paid to a creditor of its parent a total of $12,713 of principal indebtedness owed by the Company’s parent

(2) The Company has made payments of $4,610 to David Koos in satisfaction of $4,610 of indebtedness owed to David Koos by the Company’s parent

(3) The Company has paid $6,369 of expenses incurred by the Company’s parent on its behalf.

Between the period beginning September 1, 2013 and ending March 31, 2013 the Company made payments of $28,117 to Entest Biomedical, Inc. on behalf of its parent. During the quarter ended June 30, 2014 the Company paid 6,778 to Entest Biomedical , inc. to be applied against debt owed by Bio Matrix Scientific group , inc. to Entest Biomedical Inc.

During the quarter ended June 30, 2014 the Company has paid $1,880 of expenses incurred by the Company’s parent on its behalf.

NOTE 8. STOCKHOLDERS' EQUITY

The stockholders' equity section of the Company contains the following classes of capital stock as June 30, 2014:

Common stock, $ 0.0001 par value; 500,000,000 shares authorized: 51,907,917 shares issued and outstanding.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.

Preferred Stock, $0.0001 par value, 5,000,000 shares authorized: 0 shares issued and outstanding

The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired.

NOTE 9. STOCK TRANSACTIONS

On June 26, 2014 2,083 of the issued common shares of the Company were cancelled at the request of the holder.

 Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CERTAIN FORWARD-LOOKING INFORMATION

Information provided in this Quarterly report on Form 10Q may contain forward-looking statements within the meaning of Section 21E or Securities Exchange Act of 1934 that are not historical facts and information. These statements represent the Company's expectations or beliefs, including, but not limited to, statements concerning future and operating results, statements concerning industry performance, the Company's operations, economic performance, financial conditions, margins and growth in sales of the Company's products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. The Company's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company with the Securities and Exchange Commission. All references to” We”, “Us”, “Company” or the “Company” refer to Regen BioPharma, Inc.

Material Changes in Financial Condition

As of June 30, 2014, we had Cash on Hand of $ 49,395 and as of September 30, 2013 we had Cash on Hand of $115,922.

The decrease Cash on Hand of approximately 57 %  is primarily attributable to expenses incurred by the Company in the operation of its business offset by the issuance by the Company of 300,000 Common Shares for aggregate cash consideration of $300,000 during the quarter ended December 31, 2013and a loan to the Company of $50,000 by Bio-Matrix Scientific Group, Inc. made during the quarter ended June 30, 2014.

As of June 30, 2014 we had Notes Receivable of $2,222 and as of September 30, 2013 we had Notes Receivable of $0.

The increase in Notes Receivable of 100% is attributable to $2,222 loaned by the Company to Entest Bio-Medical, Inc during the quarter ended June 30, 2014.

As of June 30, 2014 we had Accrued Interest Receivable of $14 and as of September 30, 2013 we had Accrued Interest Receivable of$0.

The increase in of Accrued Interest Receivable of 100% is attributable to $2,222 loaned by the Company to Entest Bio-Medical, Inc during the quarter ended June 30, 2014.

 As of June 30, 2104 we had Accounts Payable of $117 and as of September 30, 2013 we had Accounts Payable of $0.

The increase in Accounts Payable of 100% is attributable to amounts owed to Securities transfer Corporation and Cox Communications.

As of June 30, 2014 we had Notes Payable of $50,000 and as of September 30, 2013 we had Notes Payable of $0

The increase in Notes Payable of 100% is attributable to a loan to the Company of $50,000 by Bio-Matrix Scientific Group, Inc. made during the quarter ended June 30, 2014.

As of June 30, 2104 we had Accrued Payroll Taxes of $7,343 and as of September 30, 2013 we had Accrued Payroll Taxes of $0.

 The increase in Accrued Payroll Taxes of 100% is attributable to employment tax liabilities incurred by the Company subsequent to September 30, 2013 but as yet unpaid.

Material Changes in Results of Operations

Revenues from continuing operations were $0 for the three months ended June 30, 2014 and -0- for the three months ended June 30, 2013.  Net Losses were $166,021 for the three months ended June 30, 2014 and $74,829 for the same period ended 2013.

The increase in Net Losses of approximately 121% is primarily attributable to

(a)	greater general and administrative and consulting expenses incurred during the quarter ended June 30, 2014 when compared to the quarter ended June 30, 2013
(b)	The recognition of $8,658 of capital contributions to Bio Matrix Scientific Group, Inc. during the quarter ended June 30, 2014.

Offset by greater Research and Development Expenses incurred during the quarter ended June 30, 2013 when compared to the same quarter ended in 2014 as well as the recognition of $504 of Other Income during the quarter ended June 30, 2014.

Revenues from continuing operations were $0 for the nine months ended June 30, 2014 and -0- for the nine months ended June 30, 2013.  Net Losses were $561,751 for the nine months ended June 30, 2014 and $237,173 for the same period ended 2013.

The increase in Net Losses of approximately 137% is primarily attributable to greater general and administrative, research and development, and consulting expenses as well as $48,510 of expenses attributable to capital Contributions to Bio-Matrix Scientific Group, Inc. incurred during the nine months ended June 30, 2014 when compared to the same period ended 2013 offset by $504 in Other Income recognized during the quarter ended June 30, 2014.

Liquidity and Capital Resources

As of June 30, 2014 we had $49,395 cash on hand and current liabilities of $57,460 such liabilities consisting of Accounts Payable, Notes Payable and Accrued Expenses. We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.

The Company plans to meet cash needs through applying for governmental and non-governmental grants as well as selling its securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings. Management can give no assurance that any governmental or non-governmental grant will be obtained by the Company despite the Company’s best efforts. As of February 19, 2014 The Company has identified the National Heart Lung and Blood Institute Clinical Trial Pilot Studies (R34) grant which provides up to $450,000 in funding over a period of three years as well as the Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications administered by the Small Business Innovation Research (SBIR) program of the National Institute of Health as grants for which the Company intends to apply.

We cannot assure that we will be successful in obtaining additional financing necessary to implement our business plan. We have not received any commitment or expression of interest from any financing source that has given us any assurance that we will obtain the amount of additional financing in the future that we currently anticipate. For these and other reasons, we are not able to assure that we will obtain any additional financing or, if we are successful, that we can obtain any such financing on terms that may be reasonable in light of our current circumstances.

We were not party to any material commitments for capital expenditures as of the end of the quarter ended June 30, 2014.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, as defined by Rule 229.10(f) (1) of Regulation S-K, we are not required to provide the information required by this Item. We have chosen to disclose, however, that we have not engaged in any transactions, issued or bought any financial instruments or entered into any contracts that are required to be disclosed in response to this item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of David Koos, who is the Company's Principal Executive Officer/Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. The Company's disclosure controls and procedures are designed to provide a reasonable level of assurance of achieving the Company's disclosure control objectives. The Company's Principal Executive Officer/Principal Financial Officer has concluded that the Company's disclosure controls and procedures are, in fact, effective at this reasonable assurance level as of the period covered.

Changes in Internal Controls over Financial Reporting

In connection with the evaluation of the Company's internal controls during the period commencing on April 1, 2014 and ending on June 30, 2014, David Koos, who is both the Company's Principal Executive Officer and Principal Financial Officer has determined that there were no changes to the Company's internal controls over financial reporting that have been materially affected, or is reasonably likely to materially effect, the Company's internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

There are no material pending legal proceedings to which the Company is a party or of which any of the Company’s property is the subject.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

None.

Item 4. Reserved

None.

Item 5. Other Information

None.

Item 6. Exhibits

10.1	Note payable to Bio Matrix Scientific Group, Inc.
10.2	Note receivable from Entest Biomedical, Inc.
31.1	Certification of Chief Executive Officer
31.2	Certification of Chief Financial Officer
32.1	Certification of Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

In accordance with the requirements of the Exchange Act, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 2,  2014	Regen BioPharma Inc. , Inc.
	a Nevada corporation
By:	/s/ David R. Koos
	David R. Koos
	Chief Executive Officer

EX-10.1

Exhibit 10.1

PROMISSORY NOTE PAYABLE

FOR VALUE RECEIVED, Regen Biopharma, Inc., a Nevada corporation (“Debtor’) , hereby promises to pay to the order of Bio Matrix Scientific Group, Inc. , a Delaware corporation, the sum of Fifty Thousand ($50,000 ) Dollars, together with simple interest thereon at the rate of 10 % per annum on the unpaid balance. Said sum shall be paid in the manner following:

Principal and/or accrued interest due hereunder shall be due and Payable , in whole or in part, at the demand of the Holder. This Note may be assigned to any third party, in whole or in part, at the sole option of Bio matrix Scientific Group, Inc. or any Holder in due course.

This Note shall be governed by and interpreted in accordance with the laws of the State of California without regard to the principles of conflicts of law. Each of the Debtor and the Holder and any Holder in due course hereby submit to the exclusive jurisdiction of the United States Federal and state courts located in san Diego , California with respect to any dispute arising under this Note.

Signed and sealed under penalty of perjury this 30^th day of June, 2014.

REGEN BIOPHARMA INC.

By: /s/David Koos

Its: CEO

ACCEPTED BY BIO-MATRIX SCIENTIFIC GROUP INC.

By: /s/David Koos

Its: CEO

EX-10.2

Exhibit 10.1

PROMISSORY NOTE PAYABLE

FOR VALUE RECEIVED, Entest Biomedical, Inc., a Nevada corporation (“Debtor’) , hereby promises to pay to the order of Regen Biopharma, Inc., a Nevada corporation, the sum of Two Thousand Two Hundred and Twenty Two ($2,222 ) Dollars, together with simple interest thereon at the rate of 10 % per annum on the unpaid balance. Said sum shall be paid in the manner following:

Principal and/or accrued interest due hereunder shall be due and Payable , in whole or in part, at the demand of the Holder. This Note may be assigned to any third party, in whole or in part, at the sole option of Regen Biopharma, Inc. or any Holder in due course.

This Note shall be governed by and interpreted in accordance with the laws of the State of California without regard to the principles of conflicts of law. Each of the Debtor and the Holder and any Holder in due course hereby submit to the exclusive jurisdiction of the United States Federal and state courts located in San Diego , California with respect to any dispute arising under this Note.

Signed and sealed under penalty of perjury this 6^th day of June, 2014.

ENTEST BIOMEDICAL INC.

By: /s/David Koos

Its:CEO

ACCEPTED BY REGEN BIOPHARMA INC.

By: /s/David Koos

Its: CEO

EX-31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David Koos, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Regen BioPharma, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 2, 2014	By:	/s/  David R. Koos
		David R. Koos  Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION OF ACTING CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David Koos, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Regen BioPharma, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 2, 2014	By:	/s/  David R. Koos
		David R. Koos  Acting Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly report of Regen BioPharma, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 2, 2014	By:	/s/  David R. Koos
		David R. Koos  Chief Executive Officer

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Regen BioPharma, Inc. and will be retained by Regen BioPharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly report of Regen BioPharma, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to her knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 2, 2014	By:	/s/  David R. Koos
		David R. Koos  Acting Chief Financial Officer

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Regen BioPharma, Inc. and will be retained by Regen BioPharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Income Taxes (Details Narrative) (USD $)	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Deferred Tax Asset	$ 368,552
Net operating loss carry forwards	$ 1,083,975
Federal corporate rate	34.00%

XML

Notes Payable

9 Months Ended

Jun. 30, 2014

Debt Disclosure [Abstract]

Notes Payable

NOTE 4. NOTES PAYABLE

	June 30, 2014		September 30, 2013
Bio Matrix Scientific Group, Inc. (Note 7)		50,000		0
Notes payable	$	50,000	$	0

$50,000 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

XML

Stock Transactions (Details Narrative)	1 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]
Common stock cancelled	2,083

XML

Going Concern

9 Months Ended

Jun. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $ 1,083,975 during the period from April 24, 2012 (inception) through June 30, 2014. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings.

XML

Balance Sheets (Unaudited) (USD $)	Jun. 30, 2014	Sep. 30, 2013
CURRENT ASSETS
Cash	$ 49,395	$ 115,922
Note Receivable	2,222	0
Accrued Interest Receivable	14	0
Total Current Assets	51,631	115,922
TOTAL ASSETS	51,631	115,922
Current Liabilities:
Accounts payable	117	0
Notes Payable	50,000	0
Accrued payroll taxes	7,343	0
Total Current Liabilities	57,460	0
Total Liabilities	57,460	0
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 51,610,000 issued and outstanding as of September 30, 2013 and 51,907,917 shares issued and outstanding June 30, 2014	5,191	5,161
Preferred Stock($.0001 par value) 5,000,000 shares authorized 0 shares issued and outstanding as of September 30, 2013 and June 30, 2014	0	0
Additional Paid in capital	485,097	185,127
Contributed Capital	587,858	447,858
Retained Earnings (Deficit) accumulated during the development stage	(1,083,975)	(522,224)
Total Stockholders' Equity (Deficit)	(5,829)	115,922
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 51,631	$ 115,922

XML

Organization and Summary of Significant Accounting Policies

9 Months Ended

Jun. 30, 2014

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company is a wholly owned subsidiary of Bio-Matrix Scientific Group, Inc, a Delaware corporation.

The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

C. DEVELOPMENT STAGE

The Company is a development stage company devoting substantially all of its efforts to establish a new business.

D. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

E. PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.

F. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level 1:  Quoted prices in active markets for identical assets or liabilities

Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

G. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30 2014 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

H.  BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

I. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarter ended June 30, 2014 and $0 for the twelve months ended September 30, 2013.

XML

Notes Receivable - Notes Receivable (Details) (USD $)	Jun. 30, 2014	Sep. 30, 2013
Receivables [Abstract]
Entest Biomedical, Inc. (Note 7)	$ 2,222	$ 0
Notes payable	$ 2,222	$ 0

XML

Income Taxes - Deferred tax assets (Details) (USD $)	Jun. 30, 2014
Deferred tax assets:
Net operating tax carry forwards	$ 368,552
Other	0
Gross deferred tax assets	368,552
Valuation allowance	(368,552)
Net deferred tax assets	$ 0

XML

Recent Account Pronouncements

9 Months Ended

Jun. 30, 2014

Accounting Changes and Error Corrections [Abstract]

Recent Account Pronouncements

NOTE 2.  RECENT ACCOUNTING PRONOUNCEMENTS

The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows.

On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.

On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position.

On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies.  Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

XML

Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Sep. 30, 2013
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	51,907,917	51,610,000
Common stock, shares outstanding	51,907,917	51,610,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML

Income Taxes (Tables)

9 Months Ended

Jun. 30, 2014

Income Tax Disclosure [Abstract]

Deferred tax assets

Deferred tax assets:
Net operating tax carry forwards	$	368,552
Other		-0-
Gross deferred tax assets		368,552
Valuation allowance		(368,552)	)
Net deferred tax assets	$	-0-

XML

Document and Entity Information	9 Months Ended
	Jun. 30, 2014	Aug. 02, 2014
Document And Entity Information
Entity Registrant Name	Regen BioPharma Inc
Entity Central Index Key	0001589150
Document Type	10-Q
Document Period End Date	Jun. 30, 2014
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		51,907,917
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2014

XML

Organization and Summary of Significant Accounting Policies (Details Narrative) (USD $)	3 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2014
Accounting Policies [Abstract]
Valuation Allowance	100.00%
Advertising expenses	$ 0	$ 0

XML

Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended		26 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Income Statement [Abstract]
REVENUES	$ 0	$ 0	$ 0	$ 0	$ 0
COST AND EXPENSES
Research and Development	0	3,000	13,867	8,394	39,976
General and Administrative	127,580	71,829	389,961	228,779	790,025
Consulting and Professional Fees	30,287	0	109,917	0	170,770
Total Costs and Expenses	157,867	74,829	513,745	237,173	1,000,771
OPERATING LOSS	(157,867)	(74,829)	(513,745)	(237,173)	(1,000,771)
OTHER INCOME & (EXPENSES)
Interest Income	14	0	14	0	14
Refunds of amounts previously paid	490	0	490	0	35,490
Capital contribution to parent	(8,658)	0	(48,510)	0	(118,708)
TOTAL OTHER INCOME (EXPENSE)	(8,154)	0	(48,006)	0	(83,204)
NET INCOME (LOSS)	$ (166,021)	$ (74,829)	$ (561,751)	$ (237,173)	$ (1,083,975)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ (0.00320)	$ (0.00310)	$ (0.01515)	$ (0.02960)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	51,909,907	24,185,714	37,082,956	8,009,891

XML

Related Party Transactions

9 Months Ended

Jun. 30, 2014

Related Party Transactions [Abstract]

Related Party Transactions

NOTE 7. RELATED PARTY TRANSACTIONS

As of June 30, 2014 the Company has received capital contributions from its parent totaling $587,858 and has issued 50,010,000 common shares to its parent for aggregate consideration of $20,090. The Company also utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 provided to the Company by Entest BioMedical, Inc. on a month to month basis free of charge. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent.

As of June 30, 2014 Entest Biomedical inc. is indebted to the Company in the amount of $2,222. $2,222 lent by the Company to Entest Biomedical, Inc . is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

As of June 30, the Company is indented to its parent in the amount of $50,000. $50,000 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

On August 20, 2013 the Company issued 1,500,000 common shares to the holder of one of its parent’s convertible notes (“Parent Convertible Note Holder”) in satisfaction of $70,198 owed by the Company’s parent to the Parent Convertible Note Holder. During the three months ended December 31, 2013

(1) The Company has paid to a creditor of its parent a total of $12,713 of principal indebtedness owed by the Company’s parent

(2) The Company has made payments of $4,610 to David Koos in satisfaction of $4,610 of indebtedness owed to David Koos by the Company’s parent

(3) The Company has paid $6,369 of expenses incurred by the Company’s parent on its behalf.

Between the period beginning September 1, 2013 and ending March 31, 2013 the Company made payments of $28,117 to Entest Biomedical, Inc. on behalf of its parent. During the quarter ended June 30, 2014 the Company paid 6,778 to Entest Biomedical , inc. to be applied against debt owed by Bio Matrix Scientific group , inc. to Entest Biomedical Inc.

During the quarter ended June 30, 2014 the Company has paid $1,880 of expenses incurred by the Company’s parent on its behalf.

XML

Income Taxes

9 Months Ended

Jun. 30, 2014

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 6. INCOME TAXES

As of June 30, 2014

Deferred tax assets:
Net operating tax carry forwards	$	368,552
Other		-0-
Gross deferred tax assets		368,552
Valuation allowance		(368,552)	)
Net deferred tax assets	$	-0-

As of June 30, 2014 the Company has a Deferred Tax Asset of $368,552 completely attributable to net operating loss carry forwards of approximately $ 1,083,975 (which expire 20 years from the date the loss was incurred).

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. As a result, the Company has the Company recorded a valuation allowance reducing all deferred tax assets to 0.

Income tax is calculated at the 34% Federal Corporate Rate.

XML

Notes Receivable (Details Narrative)	Jun. 30, 2014
Receivables [Abstract]
Annual interest rate on Entest note receivable	10.00%

XML

Going Concern (Details Narrative) (USD $)	3 Months Ended		6 Months Ended		26 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Total net loss	$ (166,021)	$ (74,829)	$ (561,751)	$ (237,173)	$ (1,083,975)

XML

Notes Payable (Tables)

9 Months Ended

Jun. 30, 2014

Debt Disclosure [Abstract]

Notes Payable

	June 30, 2014		September 30, 2013
Bio Matrix Scientific Group, Inc. (Note 7)		50,000		0
Notes payable	$	50,000	$	0

XML

Stockholders' Equity

9 Months Ended

Jun. 30, 2014

Equity [Abstract]

Stockholders' Equity

NOTE 8. STOCKHOLDERS' EQUITY

The stockholders' equity section of the Company contains the following classes of capital stock as June 30, 2014:

Common stock, $ 0.0001 par value; 500,000,000 shares authorized: 51,907,917 shares issued and outstanding.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.

Preferred Stock, $0.0001 par value, 5,000,000 shares authorized: 0 shares issued and outstanding

The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired.

XML

Stock Transactions

9 Months Ended

Jun. 30, 2014

Subsequent Events [Abstract]

Stock Transactions

NOTE 9. STOCK TRANSACTIONS

On June 26, 2014 2,083 of the issued common shares of the Company were cancelled at the request of the holder.

XML

Notes Receivable (Tables)

9 Months Ended

Jun. 30, 2014

Receivables [Abstract]

Notes Receivable

	June 30, 2014		September 30, 2013
Entest Biomedical, Inc. (Note 7)		2,222		0
Notes payable	$	2,222	$	0

XML

Notes Payable (Details Narrative)	Jun. 30, 2014
Debt Disclosure [Abstract]
Annual interest rate on Bio Matrix note payable	10.00%

XML

Related Party Transactions (Details Narrative) (USD $)	3 Months Ended		7 Months Ended	26 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Mar. 31, 2014	Jun. 30, 2014	Aug. 20, 2013
Related Party Transactions [Abstract]
Capital contribution received from Parent company				$ 587,858
Common shares issued to Parent company				50,010,000
Cash received for issuance of common shares				20,090
Common shares issued to holder of Parent Convertible Note					1,500,000
Amount of Parent Convertible Note satisfied					70,198
Principal indebtedness paid to creditor		12,713
Principal indebtedness paid to CEO		4,610
Paid expenses incurred by parent company	1,880	6,369
Payments to Entest Biomedical	$ 6,778		$ 28,117

XML

Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended		26 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ (561,751)	$ (231,173)	$ (1,083,975)
Adjustments to reconcile net Income to net cash
Common Stock issued for expenses	0	0	70,198
Increase (Decrease) in Accounts Payable	117	0	117
(Increase) Decrease in Notes Receivable	(2,222)	0	(2,222)
(Increase) Decrease in Interest Receivable	(14)	0	(14)
Increase (Decrease) in accrued Expenses	7,343	0	7,343
Net Cash Provided by (Used in) Operating Activities	(556,527)	(237,173)	(1,008,553)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash	300,000	20,000	420,090
Increase in Contributed Capital	140,000	219,903	587,858
Increase in Notes Payable	50,000	0	50,000
Net Cash Provided by (Used in) Financing Activities	490,000	239,903	1,057,948
Net Increase (Decrease) in Cash	(66,527)	2,730	49,395
Cash at Beginning of Period	115,922	923	0
Cash at End of Period	$ 49,395	$ 3,653	$ 49,395

XML

Notes Receivable

9 Months Ended

Jun. 30, 2014

Receivables [Abstract]

Notes Receivable

NOTE 5. NOTES RECEIVABLE

	June 30, 2014		September 30, 2013
Entest Biomedical, Inc. (Note 7)		2,222		0
Notes payable	$	2,222	$	0

$2,222 lent by the Company to Entest Biomedical, Inc . is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

XML

Stockholders' Equity (Details Narrative) (USD $)	Jun. 30, 2014	Sep. 30, 2013
Equity [Abstract]
Common stock, Par value	$ 0.0001	$ 0.0001
Common stock, authorized	500,000,000	500,000,000
Common stock issued and outstanding	51,907,917	51,610,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued and outstanding	0	0

XML

Notes Payable - Notes Payable (Details) (USD $)	Jun. 30, 2014	Sep. 30, 2013
Debt Disclosure [Abstract]
Bio Matrix Scientific Group, Inc. (Note 7)	$ 50,000	$ 0
Notes payable	$ 50,000	$ 0